Skip to main content

Table 3 Treatments and efficacy of treatments

From: A step toward essential tremor gene discovery: identification of extreme phenotype and screening of HTRA2 and ANO3

Medications

Patients (n = 54 patients)

Propranolol (n = 31 patients)

 Positive effect of propranolol

24 (77%)

 Mean posology, en milligram/day, range

109 (40–300)

 Mean length of treatment, months, range

57 (1–360)

Primidone (n = 16 patients)

 Positive effect of primidone

13 (81%)

 Mean posology, en milligram/day, range

338 (10–750)

 Mean length of treatment, months, range

15 (1–60)

Topiramate (n = 7 patients)

 Positive effect of topiramate

3 (43%)

 Mean posology, en milligram/day, range

75 (25–150)

 Mean length of treatment, months, range

11 (1–36)

Chronic high frequency thalamic stimulation

2 (4%)